Vertex Pharmaceuticals 3Q Profit Rises on Continued Sales Strength
06 Novembro 2023 - 6:46PM
Dow Jones News
By Ben Glickman
Vertex Pharmaceuticals' profit rose in the third quarter on
continued strength in sales of its cystic fibrosis treatments.
The Boston-based drugmaker posted a third-quarter profit of
$1.04 billion, or $3.97 a share, compared with $930.5 million, or
$3.59 a share, a year earlier. Analysts polled by FactSet expected
per-share earnings of $3.50.
Stripping out certain one-time items, adjusted per-share
earnings came to $4.08, ahead of the $3.92 forecast by analysts,
according to FactSet.
Revenue rose 6% to $2.48 billion, missing the $2.5 billion
expected by analysts polled by FactSet.
The results were lifted by strong sales of Vertex's cystic
fibrosis drug Trikafta, including the launch of the drug in
children age two to five, the company said.
Vertex said revenue growth, higher interest income and lower tax
expense, were offset by increased investment in the company's
pipeline and the cost to support drug launches.
The company increased its full-year guidance for cystic-fibrosis
product revenue to $9.85 billion, compared with prior guidance of
$9.7 billion to $9.8 billion.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
November 06, 2023 16:31 ET (21:31 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Vertex Pharmaceuticals (NASDAQ:VRTX)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Vertex Pharmaceuticals (NASDAQ:VRTX)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024